



# HHS Public Access

Author manuscript

*Small.* Author manuscript; available in PMC 2021 October 04.

Published in final edited form as:

*Small.* 2020 October ; 16(43): e2004205. doi:10.1002/sml.202004205.

## Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma

**Trevor Stack,**

Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA

**Michael Vincent,**

Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA

**Amir Vahabikashi,**

Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA

**Guorong Li,**

Department of Ophthalmology, Duke University, 2351 Erwin Road, Durham, NC 27710, USA

**Kristin M. Perkumas,**

Department of Ophthalmology, Duke University, 2351 Erwin Road, Durham, NC 27710, USA

**W. Daniel Stamer,**

Department of Ophthalmology, Duke University, 2351 Erwin Road, Durham, NC 27710, USA

Department of Biomedical Engineering, Duke University, 101 Science Drive, Durham, NC 27708, USA

**Mark Johnson,**

Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA

Department of Ophthalmology, Northwestern University, 645 N. Michigan Avenue, Chicago, IL 60611, USA

Department of Mechanical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA

**Evan Scott**

Department of Biomedical Engineering, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, USA

### Abstract

---

evan.scott@northwestern.edu.


Supporting Information

Supporting information, including detailed methods, are provided in the Supplemental Material.

Increased stiffness of the Schlemm's canal (SC) endothelium in the aqueous humor outflow pathways has been associated with elevated intraocular pressure (IOP) in glaucoma. Novel treatments that relax this endothelium, such as actin depolymerizers and rho kinase inhibitors, are in development. Unfortunately, these treatments have undesirable off-target effects and a lower than desired potency. To address these issues, we have developed a targeted PEG-*b*-PPS micelle loaded with actin depolymerizer latrunculin A ( $\Delta$ LatA-MC). Targeting of SC cells was achieved by modifying the micelle surface with a high affinity peptide that binds the VEGFR3/FLT4 receptor, a lymphatic lineage marker found to be highly expressed by SC cells relative to other ocular cells. During *in vitro* optimization, increasing the peptide surface density increased micellar uptake in SC cells while unexpectedly decreasing uptake by human umbilical vein endothelial cells (HUVEC). The functional efficacy of  $\Delta$ LatA-MC, as measured by decreased SC cell stiffness compared to non-targeted micelles (ntLatA-MC) or targeted blank micelles (tBL-MC), was verified using atomic force microscopy.  $\Delta$ LatA-MC reduced IOP in an *in vivo* mouse model by 30–50%. Our results validate use of a cell-softening nanotherapy to selectively modulate stiffness of SC cells for therapeutic reduction of IOP and treatment of glaucoma.

## Graphical Abstract

### Cell Softening Nanotherapy for Glaucoma



## Keywords

Glaucoma; Endothelium; Latrunculin; Nanoparticle; Controlled Delivery; targeted drug delivery vehicles; cell softening nanotherapies

Glaucoma is the leading cause of irreversible blindness, affecting millions of people worldwide<sup>[1]</sup>. The elevated IOP characteristic of glaucoma is caused by increased resistance to the outflow of aqueous humor from the eye. This increased resistance is thought to be generated either at or very near the inner wall endothelial lining of SC and has been tied to increased stiffness of the SC endothelial cells and their substrate<sup>[2,3]</sup>. Mechanistically, it appears that increased stiffness of the SC cells impairs the formation of pores in this endothelial barrier, thereby increasing outflow resistance and IOP<sup>[2]</sup>.

This pathological defect is not targeted by traditional glaucoma pharmacological therapies that act by either decreasing aqueous humor secretion or by increasing unconventional outflow, a separate pathway by which aqueous humor can flow out of the eye<sup>[4]</sup>. Rho kinase inhibitors and actin depolymerizers are two classes of drugs recently introduced that relax and soften the outflow tissue cells, thereby lowering aqueous humor outflow resistance<sup>[4,5]</sup>. While these drugs are effective at lowering the elevated IOP associated with glaucoma, they are hindered by prevalent, local side effects including conjunctival hyperemia, subconjunctival hemorrhages, corneal verticillata and other corneal abnormalities associated with blurry vision including irregularly-shaped corneal endothelial cells and guttata-like changes<sup>[6,7]</sup>.

Due to these adverse off-target effects, we sought to develop and optimize a nanocarrier platform employing a targeting moiety for selective intracellular delivery to SC cells as a glaucoma treatment strategy. Nanomaterials have been shown to be advantageous drug delivery platforms that are well-suited for targeting specific cells and tissues<sup>[8,9]</sup>. Enhanced targeting and cell specificity allows for less off-target drug delivery and a lower potential for side effects<sup>[10]</sup>. Targeted nanomaterials have been shown to lower the therapeutic threshold concentration for certain drugs after encapsulation as well as reduce cytotoxicity and other unwanted effects in many cell types including SC cells<sup>[11–13]</sup>.

Latrunculin is a well-known transient actin depolymerizing agent that mechanically softens cells<sup>[14]</sup> and has been shown to significantly reduce IOP in animal studies<sup>[5,15]</sup>. A phase I clinical trial, at concentrations previously found to be effective in primates, found a modest reduction of IOP with side effects that included mild redness, irritation, and a transient increase in central corneal thickness<sup>[16]</sup>. We speculated that targeted delivery of latrunculin to SC cells would provide increased bioavailability while minimizing side effects. Self-assembled poly (ethylene glycol)-*b*-poly(propylene sulfide) (PEG-*b*-PPS) block co-polymers have been used as versatile nanocarriers in a wide range of applications<sup>[12,17–23]</sup>. Depending on the morphology employed, PEG-*b*-PPS nanocarriers can retain both hydrophobic and hydrophilic payloads respectively in their cores or aqueous interior compartments<sup>[20,21,24–26]</sup> and are highly customizable through control of charge, size, and targeting moieties on their surfaces<sup>[8,27]</sup>. Nanomaterials provide a wide range of options for sustained drug and gene delivery<sup>[19,22,28]</sup>, and the development of SC targeted nanocarriers will thus provide versatile options for the long term delivery of glaucoma therapeutics following a single intracameral injection. Here, we report on the design and development of a PEG-*b*-PPS controlled delivery system to deliver latrunculin A to SC cells.

SC cells express the lymphatic lineage receptor VEGFR3/FLT4 at moderately high levels as compared with blood vascular cells, which lack this receptor<sup>[29]</sup>. PEG-*b*-PPS micellar nanocarriers decorated with a FLT4-specific targeting peptide and loaded with latrunculin A were generated. The targeting and functional efficacy of this formulation was assessed *in vitro* in SC cells using uptake assays and atomic force microscopy (AFM). *In vivo* efficacy was evaluated using a C57BL/6J mouse model by measuring changes in IOP over multiple days after administering targeted nanocarriers intracamerally. Results show that the targeted nanocarriers were highly selective for SC cells in comparison with blood vascular cells, and that targeted latrunculin-loaded micelles (*t*LatA-MC) significantly lowered IOP in mouse eyes, as compared to control eyes treated with non-targeted latrunculin-loaded micelles (*n*LatA-MC).

### **Peptide lipid constructs can be attached to PEG-*b*-PPS micelles for intracellular delivery to SC endothelial cells with high efficiency and do not influence micelle structure.**

VEGFR3/FLT4 is a lymphatic marker that is expressed at the surface of SC endothelial cells<sup>[30,31]</sup>. We hypothesized that displaying a ligand for this receptor at the micelle surface would enhance micelle uptake selectively by SC cells as compared with other ocular cells, particularly blood vascular cells. We examined expression of FLT4 in human SC cells and human umbilical vein endothelial cells (HUVEC; used as a generic blood vascular cell control). Schlemm's cells were isolated as previously described<sup>[32]</sup> and HUVEC were obtained from Lonza (Basel, Switzerland). Cells were prepared as described in the methods (see Supplementary Material for all detailed methods) and labeled with anti-FLT4 antibody. FLT4 expression was evaluated using laser scanning confocal microscopy, widefield fluorescence microscopy, and flow cytometry. As expected, FLT4 was present on the SC cell surface at significantly higher abundance than the HUVEC cell surface (Figure 1A, B, S1).

Targeted micelles were developed that incorporated an FLT4-targeting ligand (*t*BL-MC, and *t*LatA-MC; (BL=blank, *t*=peptide target) (Figure 1C). Several peptide sequences binding FLT4 were previously identified using phage display<sup>[33]</sup>. The highest affinity peptide sequence, WHWLPNLRHYAS, was selected as a targeting moiety and attached to a palmitoleic acid tail via a PEG spacer (Figure 1D). We have previously used constructs of this format with polymersomes for optimization of cell-selective targeting<sup>[8]</sup>. This targeting peptide construct was synthesized by solid phase peptide synthesis and was purified using preparatory HPLC. The resulting peptide construct had a mass of 2151 g/mol as assessed by LC-MS and was of high purity ( > 95% pure; Figure 1E). Micelles were formed via the co-solvent evaporation method and separate batches were pooled and then separated into blank MC (BL-MC), non-targeted LatA-MC (*nt*-LatA-MC), and targeted LatA-MC (*t*LatA-MC) formulations. *t*LatA-MC formulations were generated by incubating PEG-*b*-PPS micelles on an end-to-end shaker with 5% molar ratio of the peptide construct to PEG-*b*-PPS copolymer. Latrunculin A content of the micelles was quantified using HPLC as previously described<sup>[11]</sup>, and loading efficiency was found to vary between 55% and 65% across multiple formulations. Peptide incorporation did not alter latrunculin A content of the micelles (Table S1).

We next evaluated the tLatA-MC formulations for peptide incorporation using fluorescence spectroscopy. The tryptophan residues on the FLT4 targeting peptide grant the construct an intrinsic fluorescence that can be measured against a standard curve to determine peptide concentrations within the micelles (Figure S2). Incorporation efficiencies of 91% or above were found for all measured molar ratios (Figure 1F). Formulations were evaluated by transmission electron microscopy (TEM) and dynamic light scattering (DLS) to characterize size, polydispersity, and morphology (Fig. 1G). TEM characterization confirmed micelles prepared with peptide form successfully and are not disrupted by peptide embedding (Figure 1G). There were not significant differences in micelle size between the groups (Table S1). We further characterized the micelle formulations with SAXS using synchrotron radiation (Figure 1H). A core shell model was fit to each scattering profile, and the core shell radius and shell thickness of the micelles were estimated. Minimal differences in micelle dimensions were found between blank and peptide-displaying formulations (Figure 1H). These results are consistent with our previous findings that neither Latrunculin A loading nor incorporation of targeting peptide via lipid anchoring alter the size or structure of micelles<sup>[8],[11]</sup>.

### **tLatA-MC demonstrated significantly greater uptake by SC cells and cell softening compared to non-targeted micelles *in vitro*.**

To evaluate the targeting efficacy of the FLT4 binding peptide, we examined the uptake of micelles. SC cells and HUVEC were incubated with 0.5 mg/mL Alexa 555 labeled micelles incorporated with various molar ratios (1%, 3%, 5%) of peptide to micelle for 1 hour at 37°C. Afterwards, cells were washed, harvested, and evaluated for particle uptake and cytotoxicity by flow cytometry. Flow cytometric analysis demonstrated that 5% peptide incorporation into targeted blank micelles (tBL-MC) modestly increased the number of particles internalized by SC cells as compared to ntBL-MC and 1% tBL-MC (Figure 2A, B). Peptide incorporation significantly increased the number of particles internalized by SC cells as compared to HUVECs (Figure 2B). This was primarily due to unexpectedly decreased micellar uptake by HUVEC as compared to blank MCs, which to our knowledge is a phenomenon not previously reported. This result may be related to altered cell membrane interactions caused by the palmitoleic acid in the targeted micelles<sup>[34]</sup>.

When latrunculin A was loaded into micelles, the uptake by both cell types was altered. The decrease in uptake of targeted micelles (tBL-MC) by HUVECs, as compared with blank micelles (BL-MC), is no longer observed with latrunculin-loaded targeted micelles (tLatA-MC) (Figure 2C). In SC cells, there was a statistically significant increase in all cases when peptide was incorporated as compared to blank micelles (Figure 2C). SC cells demonstrated even greater uptake of the Latrunculin A loaded constructs with and without peptide than the HUVEC. This difference increases considerably for the Lat A formulations, suggesting incorporation of Lat A alters the uptake pattern of micelles in both SC cells and HUVECs, perhaps by changing micellar properties that were not examined or through effects of Lat A on the cells. This phenomenon is of significant interest and is currently under additional investigation.

To evaluate the functional effects of  $\Delta$ LatA-MC on cultured human SC cells, we used atomic force microscopy (AFM) to assess changes in cell stiffness and morphology (Figure 2D, E) following treatment of SC cells with  $\Delta$ LatA-MC (0.05  $\mu$ M Latrunculin A and 5% peptide by molar ratio) as compared with concentration-matched ntLatA-MC and micelle controls prepared without Latrunculin A (BL-MC and tBL-MC) or a PBS vehicle control for 2 hours. Latrunculin A-induced alterations in cell morphology, particularly the rounding of cell shape, indicative of cell softening<sup>[2,14]</sup>, was observed by phase contrast microscopy (Figure 2D). At this low concentration of latrunculin, only  $\Delta$ LatA-MC significantly reduces SC cell stiffness (Figure 2E). These data show that embedding the targeting peptide into the micelles increases the functional efficacy of the formulation in inducing cell softening of SC cells at low latrunculin concentrations as compared to ntLatA-MC.

### **tLatA-MC reduces IOP in C57Bl6 mice.**

We next evaluated the efficacy of our  $\Delta$ LatA-MC formulation *in vivo*. Two different *in vivo* trials were performed (Figure 3A); in the first, mice received intracameral injections of targeted latrunculin A-loaded  $\Delta$ LatA-MC or blank micelle formulation, ntBL-MC.  $\Delta$ LatA-MC significantly decreased IOP by 49% compared to blank MC at 24 hours (Figure 3B).

We further evaluated the *in vivo* efficacy of tLatA-MC in a second trial designed to include non-targeted latrunculinA-loaded micelles, ntLatA-MC (Figure 3A). Trial 2 revealed that  $\Delta$ LatA-MC significantly reduced IOP by 30% and 31% compared to ntLatA-MC and BL-MC, respectively, at 24 hours (Figure 3C). LatA-MC concentrations for both trials can be found in Figure S3. Contralateral eyes that did not receive injection showed a consistent baseline for all three groups (Figure S4). These data indicate that incorporation of FLT4 peptide into latrunculin A-loaded micelle formulations significantly lowered IOP in mice whereas non-targeted micelles did not. These results confirmed our observations in cultured cells probed by AFM (Figure 2D, E), where only peptide-targeted micelles significantly increased the efficacy of encapsulated latrunculin A.

The lack of effect of ntLatA-MC alone was unexpected but could be due to increased uptake in trabecular meshwork cells of ntLatA-MC that leads to a lower than threshold dose of LatA to be delivered to SC cells. Additionally, SC cells are only moderately phagocytic<sup>[11]</sup>, and the targeting peptide may be required to reach intracellular threshold concentrations necessary for therapeutic effect.

In conclusion, we have successfully developed a targeted PEG-*b*-PPS nanocarrier system loaded with actin depolymerizing/cell softening agent latrunculin A (tLatA-MC). These micellar nanocarriers were designed with an FLT4-binding peptide to target SC cells in the eye. This system can load a variety of hydrophobic drug payloads and targeting moieties. Interestingly, the tBL-MC showed a decrease in HUVEC uptake although tLatA-MC did not. This is to our knowledge a previously unreported phenomenon and suggest that we not only can target the SC cells, but greatly reduce non-specific binding. Further work also must be undertaken to determine if this phenomenon is limited to HUVECs.

The data indicating tLatA-MC reduced IOP in two sets of mouse trials demonstrates the potential clinical significance of this delivery platform. Further studies will be necessary to demonstrate that use of these targeted nanocarriers reduce off target effects, as our data suggests, and also to investigate use of this delivery platform in other settings, particularly those requiring targeted delivery of hydrophobic drugs.

### Study approval.

Mice were handled in accordance with an approved protocol (A001-19-01) by Institutional Animal Care and Use Committee of Duke University and in compliance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements

TS, MJ, and EAS designed the study. TS, MV, MJ, WDS, AV and EAS contributed to the writing of the manuscript. TS, MV and AV conducted the in-vitro experiments. WDS and KMP contributed human SC endothelial cells for use in this study. TS, MV, GL, WDS, MJ, and EAS contributed to the design and execution of the mouse studies.


Peptide Synthesis and characterization was performed at the Peptide Synthesis Core Facility of the Simpson Querrey Institute at Northwestern University. This facility has current support from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS – 1542205). AFM studies were performed at SPID facility of Northwestern University's NUANCE Center, which has received support from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-1542205). This work made use of the IMSERC at Northwestern University, which has received support from the Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-1542205), the State of Illinois, and the International Institute for Nanotechnology (IIN). Funding for *in vitro* studies was provide by NIH grant 1R01EY019696 while animal studies were funded by 1R0EY022359.

### References

- [1]. Quigley HA, Broman AT, Br J Ophthalmol 2006, 90, 262. [PubMed: 16488940]
- [2]. Overby DR, Zhou EH, Vargas-Pinto R, Pedrigi RM, Fuchshofer R, Braakman ST, Gupta R, Perkumas KM, Sherwood JM, Vahabikashi A, Dang Q, Kim JH, Ethier CR, Stamer WD, Fredberg JJ, Johnson M, Proc Natl Acad Sci U S A 2014, 111, 13876. [PubMed: 25201985]
- [3]. Vahabikashi A, Gelman A, Dong B, Gong L, Cha EDK, Schimmel M, Tamm ER, Perkumas K, Stamer WD, Sun C, Zhang HF, Gong H, Johnson M, PNAS 2019, 116, 26555.
- [4]. Tanna AP, Johnson M, Ophthalmology 2018, 125, 1741. [PubMed: 30007591]
- [5]. Peterson JA, Tian B, Bershady AD, Volberg T, Gangnon RE, Spector I, Geiger B, Kaufman PL, Invest. Ophthalmol. Vis. Sci 1999, 40, 931. [PubMed: 10102290]
- [6]. Andrés-Guerrero V, García-Feijoo J, Konstas AG, Adv Ther 2017, 34, 1049. [PubMed: 28349508]
- [7]. Tanna AP, Esfandiari H, Teramoto K, J. Glaucoma 2020, DOI 10.1097/IJG.0000000000001507.
- [8]. Yi S, Zhang X, Sangji MH, Liu Y, Allen SD, Xiao B, Bobbala S, Braverman CL, Cai L, Hecker PI, DeBerge M, Thorp EB, Temel RE, Stupp SI, Scott EA, Advanced Functional Materials 2019, 29, 1904399.
- [9]. Yoo J, Park C, Yi G, Lee D, Koo H, Cancers 2019, 11, 640.
- [10]. Scott EA, Karabin NB, Augsornworawat P, Annu Rev Biomed Eng 2017, 19, 57. [PubMed: 28226216]


- [11]. Stack T, Vahabikashi A, Johnson M, Scott E, J Biomed Mater Res A 2018, 106, 1771. [PubMed: 29468812]
- [12]. Allen SD, Liu Y-G, Kim T, Bobbala S, Yi S, Zhang X, Choi J, Scott EA, Biomater. Sci 2019, 7, 657. [PubMed: 30601470]
- [13]. Allen SD, Liu Y-G, Bobbala S, Cai L, Hecker PI, Temel R, Scott EA, Nano Res. 2018, 11, 5689.
- [14]. Spector I, Shochet NR, Blasberger D, Kashman Y, Cell Motil. Cytoskeleton 1989, 13, 127. [PubMed: 2776221]
- [15]. Peterson JA, Tian B, McLaren JW, Hubbard WC, Geiger B, Kaufman PL, Invest. Ophthalmol. Vis. Sci 2000, 41, 1749. [PubMed: 10845595]
- [16]. Rasmussen CA, Kaufman PL, Ritch R, Haque R, Brazzell RK, Vittitow JL, Transl Vis Sci Technol 2014, 3, DOI 10.1167/tvst.3.5.1.
- [17]. Scott EA, Stano A, Gillard M, Maio-Liu AC, Swartz MA, Hubbell JA, Biomaterials 2012, 33, 6211. [PubMed: 22658634]
- [18]. Yi S, Allen SD, Liu Y-G, Ouyang BZ, Li X, Augsornworawat P, Thorp EB, Scott EA, ACS Nano 2016, 10, 11290. [PubMed: 27935698]
- [19]. Karabin NB, Allen S, Kwon H-K, Bobbala S, Firlar E, Shokuhfar T, Shull KR, Scott EA, Nature Communications 2018, 9, 624.
- [20]. Vasdekis AE, Scott EA, O'Neil CP, Psaltis D, Hubbell Jeffrey. A., ACS Nano 2012, 6, 7850. [PubMed: 22900579]
- [21]. Allen S, Vincent M, Scott E, J Vis Exp 2018, DOI 10.3791/57793.
- [22]. Bobbala S, Allen SD, Yi S, Vincent M, Frey M, Karabin NB, Scott EA, Nanoscale 2020, 12, 5332. [PubMed: 32090217]
- [23]. Yi S, Karabin NB, Zhu J, Bobbala S, Lyu H, Li S, Liu Y, Frey M, Vincent M, Scott EA, Front Bioeng Biotechnol 2020, 8, DOI 10.3389/fbioe.2020.00542. [PubMed: 32047745]
- [24]. Bobbala S, Allen SD, Scott EA, Nanoscale 2018, 10, 5078. [PubMed: 29255814]
- [25]. Stano A, Scott EA, Dane KY, Swartz MA, Hubbell JA, Biomaterials 2013, 34, 4339. [PubMed: 23478034]
- [26]. Dowling DJ, Scott EA, Scheid A, Bergelson I, Joshi S, Pietrasanta C, Brightman S, Sanchez-Schmitz G, Van Haren SD, Ninkovi J, Kats D, Guiducci C, de Titta A, Bonner DK, Hirose S, Swartz MA, Hubbell JA, Levy O, J. Allergy Clin. Immunol 2017, 140, 1339. [PubMed: 28343701]
- [27]. Vincent MP, Bobbala S, Karabin NB, Frey M, Liu Y, Navidzadeh JO, Stack T, Scott EA, bioRxiv 2020, 2020.04.24.060772.
- [28]. Piotrowski-Daspit AS, Kauffman AC, Bracaglia LG, Saltzman WM, Advanced Drug Delivery Reviews 2020, DOI 10.1016/j.addr.2020.06.014.
- [29]. Aspelund A, Tammela T, Antila S, Nurmi H, Leppänen V-M, Zarkada G, Stanczuk L, Francois M, Mäkinen T, Saharinen P, Immonen I, Alitalo K, J Clin Invest 2014, 124, 3975. [PubMed: 25061878]
- [30]. Dautriche CN, Tian Y, Xie Y, Sharfstein ST, Journal of Functional Biomaterials 2015, 6, 963. [PubMed: 26402712]
- [31]. Kizhatil K, Ryan M, Marchant JK, Henrich S, John SWM, PLoS Biol. 2014, 12, e1001912. [PubMed: 25051267]
- [32]. Stamer WD, Roberts BC, Howell DN, Epstein DL, Invest. Ophthalmol. Vis. Sci 1998, 39, 1804. [PubMed: 9727403]
- [33]. Shi L-F, Wu Y, Li C-Y, J Gynecol Oncol 2015, 26, 327. [PubMed: 26197772]
- [34]. Sahay G, Batrakova EV, Kabanov AV, Bioconjug Chem 2008, 19, 2023. [PubMed: 18729494]
- [35]. Cerritelli S, Velluto D, Hubbell JA, Biomacromolecules 2007, 8, 1966. [PubMed: 17497921]
- [36]. Vargas-Pinto R, Gong H, Vahabikashi A, Johnson M, Biophys. J. 2013, 105, 300. [PubMed: 23870251]




**Figure 1.**

The design of PEG-*b*-PPS micelles that target SC cells in the anterior segment of the eye. A, B) Human SC cells express Flt4/VEGFR3. A) Representative confocal microscopy images of SC endothelial cells that were stained with anti-FLT4 antibody to confirm presence of FLT4 on the cell surface. Cells were stained with Hoescht 33342 (blue) and FLT4 (red) B) Flow cytometry data comparing median fluorescence intensity (MFI) of SC cells and HUVECs stained with anti-FLT4 antibodies. Data shown as mean $\pm$ SEM. Significance determined by unpaired t-test (\*\*\*\* $p$ <0.0001). C) Schematic representation of peptide-

displaying micelles. D) The peptide targeting construct consisting of targeting peptide, PEG spacer and palmitoleic acid tail. E) LCMS spectra of the purified Flt4-targeting peptide construct. F) Peptide loading efficiency of PEG 6 peptide construct into PEG-*b*-PPS micelles at various molar ratios as determined by tryptophan fluorescence measurements. Data shown as mean  $\pm$ SD, N=3 technical replicates. G) STEM micrograph of negatively stained PEG-*b*-PPS micelles (MC) displaying the peptide targeting construct (5%) (200,000X magnification). H) Synchrotron small angle x-ray scattering (SAXS) plots for Blank micelles, and micelles displaying the targeting peptide at 1% and 5% molar ratios. A core shell model (solid line) was fit to the data (gray points). The core radius ( $r_c$ ), shell thickness ( $r_t$ ), and total MC radius ( $r$ ) is displayed together with the chi square ( $\chi^2$ ) value for the final model fit.



**Figure 2.** The micellar display of a FLT4-binding peptide targets the delivery of Lat A to SC endothelial cells *in vitro*. A-C) The FLT4-targeting peptide enhances micelle uptake by SC endothelial cells and decreases uptake by HUVEC. A) Nanoparticle formulation abbreviations. B) unloaded micelles, C) micelles loaded with latrunculin (LatA). Cells were incubated for 1 h with Alexa 555 labeled micelles incorporated with various molar ratios (1%, 3%, 5%) of peptide to micelle. After 1 h incubation, cells were washed, harvested and fixed for analysis via flow cytometry. Median fluorescence intensity (MFI) was measured to quantify uptake of the various formulations by both cell types. Data shown as mean  $\pm$  SEM (n=3 biological replicates). In B, significance determined by one way ANOVA for each of the two cell types with *post hoc* Tukey's multiple comparisons test (‡‡‡‡ p<0.0001, ‡p<0.05). In B, C) Two way ANOVA was used to evaluate differences between all groups with *post hoc* Sidak's multiple comparisons test (\*\*\*\*p<0.0001, \*p<0.05). D-E) Targeted delivery of Lat A decreases the stiffness of human SC cells. D) Representative images taken during AFM measurements of cells treated for 2 hours with BL-MC, tBL-MC (0.97 mg/mL), ntLatA-MC, or tLatA-MC (0.05  $\mu$ M Lat A, 0.97 mg/mL); AFM tip is at top of each panel. E) Stiffness of SC cells after 2 h was determined by AFM; data shown is geometric mean  $\pm$  SD ( $\geq$ 5 measurements/condition). In E, significance determined by ANOVA with *post hoc* Tukey's multiple comparisons test (\*p<0.05).

**Figure 3.**

Targeted delivery of latrunculin reduces IOP in mouse eyes. A) Illustrative overview of experiments which consisted of 2 different IOP measurement schedules. Trial #1 and Trial #2 IOP timepoints shown with black and grey arrows respectively. B) Trial 1 results. The first trial consisted of 2 µL intracameral injection of BL-MC or tLatA MC (40 mg/mL, 5% Peptide, 17 µM Lat A) in 5 mice. IOP was measured prior to injection, and after 24 h and 48 h. C) Trial 2 results. 2 µL of BL-MC, ntLatA-MC, or tLatA-MC (15.5 µM Lat A, 40 mg/mL 5% peptide) micelles were injected into 1 eye of 5 mice each. IOP was measured prior to injection and at three timepoints during a 48 h time course. Intraocular pressure (IOP) is measured by rebound tonometry (TonoLab; Icare). Data shown are mean ± SEM (n=5). Trial #1 significance determined by unpaired t-test (\*p<0.003). Trial #2 significance determined by ANOVA with *post hoc* Tukey's multiple comparisons test (\*p<0.03).